Skip to Main Content

laboratories

  • sam patrick posted an article
    MUSC exploring a promising new approach to treating Alzheimer’s see more

    Compliments of MUSC Catalyst News

    Alzheimer’s disease is an enormous problem that, with an aging population, will only become bigger. More than 6 million Americans are living with Alzheimer’s disease, and 1 in 3 seniors will die of it, according to the Alzheimer’s Association. By 2050, the cost of Alzheimer’s disease, currently estimated at $355 billion, will rise to $1.1 trillion.

    Could one of the causes of such a huge and costly problem be traced back to the cells that line the body’s tiniest blood vessels?

    A new study published by a Medical University of South Carolina (MUSC) research team in Molecular Therapy suggests that the answer is yes.  The team, led by Hongkuan Fan, Ph.D., associate professor in the Department of Pathology and Laboratory Medicine, found fewer of these cells, known as pericytes, in the brains of people who died of Alzheimer’s disease. They also found higher levels of Fli-1, a protein most often found in blood cells and thought to govern their development.  

    When the team blocked, or inhibited, the action of Fli-1 in a mouse model of Alzheimer’s disease, the memory of the mice improved. Blocking the protein also stopped immune cells from leaking into the brain and causing the inflammation that is a hallmark of Alzheimer’s disease. Blocking Fli-1 could be a promising new approach to treating Alzheimer’s disease and other dementias. Click to continue enjoying the complete article.

  • sam patrick posted an article
    Rebuttal to a factually inaccurate and decidedly slanted article about a member of SC life sciences see more

    South Carolina is blessed with over 1,000 life sciences organizations, engaged in biotechnology and pharmaceuticals to medical devices and health IT. Never was this more important than during the pandemic, when millions were hospitalized and too many lives lost.

    As neighbors fell ill, our industry -- including Charles River Laboratories professionals -- stepped up. Over 100 organizations produced PPE, tested for COVID-19, conducted vaccine clinical trials, and expedited health solutions. Gov. McMaster expressed appreciation by declaring Life Sciences Week in South Carolina.

    As our state’s voice of life sciences, SCBIO wishes your “Monkeys & Blood” article had highlighted Charles River’s globally celebrated work that helps save millions of lives and improves patient safety.

    Carefully obtained from Atlantic horseshoe crabs by Charles River professionals, Limulus amebocyte lysate (LAL) is critical to saving lives of patients everywhere. The unique, natural substance is used to test every injectable pharmaceutical, implantable medical device, and approved COVID-19 vaccine against contamination. Without it, endotoxins could enter the body and produce life-threatening sepsis.

    For decades, Charles River has protected and nurtured our crab population. Its microbial testing is considered best-in-class by scientists globally. And with synthetic LAL neither readily available nor FDA-licensed, industry experts decline its sole use because the safety of IVs, vaccines and more would not be assured as with natural LAL.

    Charles River and our life sciences ecosystem make tremendous contributions to our state and the health of mankind. Their lifesaving medical innovations should be celebrated.

    James Chappell, CEO of SCBIO

  • sam patrick posted an article
    Expands Prisma Health patient access to laboratory testing see more

    Prisma Health has struck up a partnership with North Carolina-based Labcorp to apply the life science company’s technical expertise in hospital laboratories.

    In the exchange, Labcorp will acquire select assets of Prisma Health’s outreach lab operations, slated for the second half of 2022, according to a news release.

    Labcorp recently partnered with Walmart to distribute at-home COVID-19 tests free of charge.

    “Prisma Health is an established leader in providing health care and diagnostic services to South Carolina residents, and its dedication to its patients closely aligns with Labcorp’s mission to improve health and improve lives,” Traci Butler, senior vice president of Labcorp Diagnostics’ Atlantic Division, said in the news release. “This relationship builds on Labcorp’s strong track record of providing the critical information that patients and providers need to make the best possible health decisions. It also underscores our commitment and dedication to the people who call the Carolinas home.”

    The new relationship will expand Prisma Health patients’ access to laboratory testing throughout South Carolina and offer individualized, dedicated support to physician practices, modeled after Labcorp’s partnerships with other health care systems, according to the release. 

     

    “Labcorp brings the scale and expertise of its internationally recognized laboratory services to help us achieve the next level of service and quality in this highly specialized area,” Clarence Sevillian, executive vice president and chief operating officer of Prisma Health, said in the release. “We pride ourselves on providing the best possible experiences for our patients and providers. This relationship is another way we are building on our strong reputation of quality care and compassionate service, helping people in communities across South Carolina live their healthiest lives.”

    Once the transactions are complete, Prisma Health patients and clinicians will have access to a spectrum of services through Labcorp’s lab test menu, along with its national network of patient service centers.

     Labcorp will also offer expanded health plan coverage, additional access to rural markets and the potential for reduced out-of-pocket lab costs for patients, according to the release. Additionally, Labcorp will collaborate with Prisma Health to provide same-day STAT testing in local communities.

    Specific terms of the transactions were not disclosed.

  • sam patrick posted an article
    Company marks announcement of Life Sciences Week in SC with major expansion of its businesses see more

     In another sign of the rapidly expanding life sciences industry in South Carolina, Diversified Medical Healthcare (DMH) today announced plans to expand operations in Greenville County, S.C. The company’s $51 million investment will create 185 new jobs.

    Founded in 2011, DMH is a holding entity with multiple brands underneath its umbrella, all dedicated to providing healthcare solutions or improved patient care on a national basis. DMH’s companies are Premier Medical Laboratory Services, CPT Medical, Vessel Medical and OnGen which between them provide expertise in the arenas of clinical reference laboratories, medical supply and equipment distribution, sterile medical manufacturing, and medical software. The companies combined serve customers in all 50 U.S. states and several foreign countries.

    The announcement was made during a special program at SCBIO 2022:  The Life Sciences Conference of South Carolina, taking place in Charleston, SC. The conference was attended by more than 500 live and virtual attendees from across the country and multiple countries, indicative of the thriving industry which has expanded rapidly across the Palmetto State. Governor Henry McMaster has proclaimed Feb. 21-25 as Life Sciences Week in the state, in honor of its rapid growth and opportunity to benefit all South Carolinians.

    “Our mission is to positively impact patient lives with solutions that drive the healthcare industry forward. All of our companies under DMH work together to address many needs within the healthcare industry,” said Diversified Medical Healthcare CEO Kevin Murdock. “We are extremely proud to expand in our home state of South Carolina to carry out that mission on a larger scale and are appreciative of everyone who helped to make this possible.”  

    The corporate headquarters of DMH is located at 6000 Pelham Road in Greenville. The announced expansion by the DMH companies will result in a portion of company operations expanding into a new 136,000 sq. ft. facility in Garlington North at 315 Tanner Price Way, Greenville, SC. The expansive facility overlooks a key interstate connector in I-85, ideal for the organization’s expanding business nationally as well as statewide.

    The expansion also will support the company’s launch of its MyHealthPro product line, which produces retail-based genetic testing kits for at-home use. The tests, which will be sold directly to consumers, identify potential genetic markers for susceptibility and identification of medical issues. Additionally, it will enable their in-house research and development team of scientists to further conduct vital research for the growth of their lab developed test offerings which serve the most up-to-date needs of the population. Through this growth, all Diversified Medical Healthcare companies will continue to fill supply chain gaps and create solutions to make healthcare more efficient and effective for improved patient outcomes.

    I am thrilled that Diversified Medical Healthcare continues to grow and succeed in South Carolina. Today’s expansion announcement once again demonstrates that South Carolina is a place where medical companies want to do business. Congratulations to DMH, and we look forward to many more years of our business partnership,” noted South Carolina Gov. Henry McMaster.

    Over the last two years of the pandemic, Diversified Medical’s companies developed groundbreaking solutions for COVID-19 and provided a testing capacity of over 100,000 tests per day with 98% result delivery in under 24 hours. Its laboratory became the trusted testing partner for state health departments and Health and Human services surge sites throughout the country. Its custom surgical procedure tray company expanded production to add in-house manufacturing of millions of COVID-19 testing kits. The company also supported development and distribution of personal protective equipment (PPE) and worked around the clock to achieve unmatched innovation in science and technology for the fight against COVID-19.

    “South Carolina’s life sciences sector is booming, and this latest expansion by Diversified Medical Healthcare in Greenville County is further testament to this critical sector’s growth. Congratulations to DMH on their success right here in South Carolina,” added Secretary of Commerce Harry M. Lightsey III.

    “We are always pleased when a homegrown organization like Diversified Medical Healthcare chooses to expand and deepen its commitment to Greenville County,” stated Greenville County Council Chairman and Greenville Area Development Corporation Board Member Willis Meadows. “The company’s expertise in medical software, sterile manufacturing, medical supply and equipment distribution, and clinical lab operations – along with its passion for being good community leaders -- fits well here, and we wish them continued success into the future.”

    The expansion is now underway and is expected to be completed by 2025. Individuals interested in joining the DMH team should email HR@DivMedInc.com.

    The Coordinating Council for Economic Development has approved job development credits related to this project. The council also awarded a $200,000 Set-Aside grant to Greenville County to assist with site preparation and building construction for the additional facility at Garlington North.

  • sam patrick posted an article
    Enzyme and protein biotech leader creates, manufactures, distributes next gen products see more

    South Carolina’s Integrated Micro-Chromatography Systems, Inc. (IMCS), a leader in recombinant enzymes and micro-chromatography technologies, was awarded $1.8 million for Phase II of its Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health/ National Institute of General Medical Sciences (NIH/NIGMS).

    Combined with earlier SBIR funding, the grant will provide scientists access to affordable gangliosides that aid in developing therapeutics and diagnostics for neurological diseases including Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.

    The NIH/NIGMS previously awarded IMCS a 4-year, $2.56 million Fast-Track Small Business Technology Transfer (STTR) grant to expand the glycan toolkit and build an extensive array of sialoglycans that advance glycobiology-related research. The combined Fast-Track grants for the projects now exceeds $5.25 million. These projects will provide the scientific community access to affordable, easy-to-use reaction kits to facilitate synthesis of various glycans to advance research into potential diagnostics and therapeutics for neurodegenerative diseases.

    The SBIR project is headed by L. Andrew Lee, Ph.D., co-founder and Chief Scientific Officer of IMCS, along with Xi Chen, Ph.D., Professor of Chemistry at the University of California, Davis. The STTR project is in collaboration with Hai Yu, Ph.D., Project Scientist at the UC-Davis.

    Glycobiology, the study of the biological impact of sugars, has gained momentum in recent years. The surfaces of viruses, bacteria, and cells of our bodies are decorated with unique sugars or glycans. Some viruses and bacteria can exploit glycans to wreak havoc on our bodies, while a lack of glycans can result in disease progression. Studies suggest that modifications to certain glycans in molecules related to the brain are implicated in the onset and progression of neurodegenerative diseases.

    To date, the high cost of reagents and materials needed for glycobiology research have contributed to few tools to study glycans. Glycan-modified cell membranes (glycolipids) and gangliosides (a component of brain matter critical to research) must be harvested from pigs, sheep, and cows as there is currently no cost-effective manufacturing process. The biosynthetic manufacturing technology used for these projects will result in animal-free gangliosides.

    Matthew Macauley, Ph.D., Assistant Professor of Chemistry at the University of Alberta, is eager to access significant quantities of gangliosides. "Some experiments with glycolipids are cost-prohibitive, but scalable and facile access to glycolipids would make such experiments financially feasible,” he noted.

    While not involved in the grant, Dr. Macauley’s lab studies glycan-binding proteins called Siglecs and their impact on disease states such as Alzheimer’s. Noting that commercially available glycolipids do not capture the diversity needed in research, he notes that reaction kits funded by the grant could be “a tremendous help for a lab that doesn't have expertise with glycan synthesis and doesn’t want to invest in getting all these enzymes expressed.”

    Research reported in this press release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Numbers R44GM139441 and R42GM143998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    About IMCS

    Integrated Micro-Chromatography Systems, Inc is a privately held biotechnology company that strives to address the growing needs of clinical and research laboratories through innovative technologies and custom solutions designed to increase testing efficiency. IMCS creates, manufactures, and distributes next-generation biotechnology products to clinical and forensic toxicology, academic research facilities, US Government agencies, and health science companies around the world.

  • sam patrick posted an article
    Challenges in locating lab space impact Palmetto State as well as life sciences hotbeds see more

    Compliments of Axios

    Office occupancy rates remain deflated across industries, but one type of workplace is in high demand: labs.

    The big picture: A number of trends — in public health, American demographics and venture capital funding — are colliding to supercharge the life sciences industry.

    Driving the news: U.S. office vacancy rates are at 17%, but lab vacancy rates are at 5%, according to a new report from the commercial real estate firm CBRE.

    Money is pouring into life sciences companies. Venture capitalists are throwing money at gene editing and other promising therapies, at the same time that an aging American population is driving up health care spending.

    • The annual amount of venture capital flowing to life sciences companies has roughly doubled since 2019 to a whopping $32 billion, per CBRE and CB Insights data in the report.
    • Federal health care spending made up around 4% of GDP in 2006, but that's expected to swell to over 8% by 2040, according to the Congressional Budget Office.

    What's happening: "This was a sector that was white-hot prior to the pandemic," says Jon Varholak, a vice chairman at CBRE who specializes in life sciences real estate. "The pandemic poured more gasoline on the fire."

    • "People now more than ever are realizing we may need to be at the ready for something like this," he says.
    • That's goading established life sciences companies to come up with innovative therapies and vaccines, and giving rise to startups that bring a fresh perspective to public health issues.

    Biotech job openings are growing at their fastest pace on record, outpacing the notoriously hot tech sector, per a CBRE analysis of Bureau of Labor Statistics data.

    Certain metro areas are benefiting from this boom more than others, according to the CBRE report.

    • In Boston, lab vacancies are at 1.7%. Demand for lab space is so high that the city's "office market has become the envy of landlords across the country," the Wall Street Journal's Peter Grant writes.
    • New York's lab vacancy rate is 1.1%, and San Francisco's is 2.6%.

    And here's another new trend: Even though life sciences jobs have traditionally been located outside of cities — where there's ample inexpensive space for big labs and campuses — the strongest demand for lab space is actually in urban areas, says Ian Anderson, CBRE’s head of office research in the Americas.

    • Employment growth between 2017 and 2020 was 25% in Middlesex County, Massachusetts — which is composed of the Greater Boston suburbs — but 35% in Boston proper.
    • Growth was around 18% in San Mateo County, California, but nearly 92% in San Francisco.
    • There's nearly 0% growth in Suffolk County, New York — which encompasses the Long Island suburbs — but over 25% in Manhattan.

    The bottom line: "The whole industry is moving closer to where the intellectual capital is," Anderson says.

  • sam patrick posted an article
    The life sciences cluster in Charleston, SC -- and across the state -- is booming see more

    Compliments of CRDA and Investment Monitor

    Aligned by a shared vision for a healthier world, a united life sciences sector is a powerful thing. In the Charleston, South Carolina, market, strong synergies between new and established businesses, academic institutions and state-led initiatives provide prime opportunities for scientific innovation and business success. A growing cluster of life science companies prove testament to the power of the region’s networks.

    When considering possible locations for a new office, laboratory or manufacturing site, life science businesses will have a long checklist. This includes a provision of talent, access to markets, ease of transport and connectivity, quality of life and support from local government. When these elements come together an additional benefit is created: a thriving scientific ecosystem that generates a virtuous circle of advantages for businesses and their employees.

    The Charleston region’s ecosystem helps companies solve business challenges and mitigate risks. As a result, an increasing number of biotech and medtech manufacturers, research laboratories and service companies are calling the area home, giving birth to a burgeoning life sciences community and all the network effects that come with it. For companies seeking to enter or expand in the US, the professional economic development organization, Charleston Regional Development Alliance, exists to guide you through the process. The Alliance provides multiple services at no cost to the company.

    Click here to continue reading the entire article.

  • sam patrick posted an article
    Clinical laboratory investing over $3 million, creating 54 new positions see more

    Luxor Scientific, LLC (Luxor), a full-service clinical laboratory serving customers nationwide, today announced plans to expand operations in Greenville County, South Carolina. The more than $3.2 million investment will create 54 new jobs.

    Luxor is a CLIA and CAP-accredited, and DEA registered full-service clinical laboratory that specializes in infectious disease, immunology, integrated oncology and genetics, chemistry and hematology research. The company is comprised of recognized experts in providing cutting-edge scientific solutions to better serve the health care community.

    “We are excited to continue Luxor Scientific’s growth and investment in Greenville. Our team has established itself as one of the best serving our community, and we are glad to be adding to our capability and to our numbers,” said Luxor Scientific, LLC Chief Strategy Officer Jay Flanagan. “We are ever thankful to Greenville County and the S.C. Department of Commerce for helping us make this expansion a reality.”

    Located at 1327 Miller Road in Greenville, Luxor’s expansion will increase the company’s research and development capacity to better serve its clientele.

    “Luxor’s expansion highlights the tremendous success life science companies are seeing throughout South Carolina,” stated South Carolina Governor Henry McMaster. “This investment will bring enhanced care and innovation to South Carolina’s health care community while also creating high-quality jobs in Greenville County.”

    Luxor was founded in 2016 by brothers Ryan and Jay Flanagan, and has grown to more than 140 employees, including world-class PhD science officers on its staff. Among their clients are S.C. Department of Health and Environmental Control (DHEC), the S.C. Department of Agriculture, the US Drug Enforcement Administration, private sector employers, hospitals, universities, clinics, and others.

    “When companies like Luxor Scientific operate in South Carolina and find success, it highlights the diversity of our state’s economy. We congratulate Luxor on this expansion in Greenville County and look forward to watching their continued work in South Carolina,” added Secretary of Commerce Harry M. Lightsey III.

    The latest expansion is expected to be completed by April 2022. Individuals interested in joining the Luxor team should visit the company’s contact webpage.

    “We are always pleased when a homegrown company like Luxor chooses to expand here in Greenville County, commented Greenville County Council Chairman and Greenville Area Development Corporation Board Member Willis Meadows. “Luxor’s leading-edge expertise in life sciences has made them a strong resource to our state and to communities across the country already, and we are delighted that they have chosen to continue that growth from right here in Greenville County.”

    # # #

    The Greenville Area Development Corporation is a non-profit organization established by Greenville County Council to promote and enhance the economic growth and development of Greenville County. Since its founding in 2001, GADC efforts have resulted in the creation of over 30,000 new jobs, nearly $6 billion in capital investment, and a cumulative economic impact of over $55 billion in Greenville County, SC -- including an economic impact of more than $6 billion annually. To learn more, please visit www.goGADC.com or call (864) 235-2008. To learn more about workforce opportunities, visit www.jobsingreenvillesc.com.

  • sam patrick posted an article
    PMLS picks new Chief Commercial Officer for fast-growing organization see more

    Premier Medical Laboratory Services (PMLS) is announcing today Jeff Schmalz as their new Chief Commercial Officer. At PMLS, Jeff will be focusing on the major disciplines impacting lab growth including partnerships, product development, clinical outreach, sales infrastructure, customer service and marketing. With 35 years of experience in multiple healthcare organizations, he brings extensive knowledge in the diagnostics and reference lab markets.

    In his latest role, he led the segment marketing and business development team responsible for integrating specialty labs, technology, and test launches that contributed to several hundred million in additional revenue growth. Jeff also oversaw the launching, branding, and commercializing of Lab Developed Tests (LTDS) over a period of 15 years for 25 test classes resulting in over $400M per year in revenue. He has founded, developed, and launched international partnerships to carry out his sales initiatives and maximize overall market share.

    “I chose to work at Premier Medical Laboratory Services because they’re an innovative and nimble company with all of the components in place to make them a national leading specialty lab,” said Jeff Schmalz. “They lead with a forward-thinking approach to unmet needs within the healthcare industry and continually build on their capabilities to bring the most advanced medical diagnostics services for better patient outcomes…and that’s something I want to be a part of and advance forward.”

    As a graduate and scholarship athlete from the University of Maryland, Jeff pursued an executive management MBA curriculum from the Kellogg School of Management. Since then, he has served as a board member for the Biomedical Marketing Association and successfully launched products at Abbot, Chiron, LabCorp, Digene, Bayer and Qiagen. He managed a team of 53 segment leaders, product managers, and marketing communication strategists by positive motivation, leading by example, and empowering them to make decisions and take initiative.

    “We are at an integral phase in our growth here at Premier Medical Laboratory Services as a top lab with the mission to bring the most advanced diagnostics to our nation,” said Kevin Murdock, CEO and Founder of PMLS. “The level of talent and experience that Jeff Schmalz possesses will help us tremendously in fulfilling our vision of improving patient lives.”

     

    ABOUT PREMIER MEDICAL LABORATORY SERVICES

    Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women's Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DIABETESPredict. For more information, please visit www.PreMedInc.com

  • sam patrick posted an article
    South Carolina life sciences is surging across the state, experts say see more

    As Published in Greenville, Columbia and Charleston Business Magazines

    When describing today’s South Carolina’s life sciences industry, words like "surging" and “booming” are often mentioned.

    Life sciences is diverse, with seven sectors: drugs and pharmaceuticals; medical devices and equipment; digital health solutions; research, medical and testing laboratories; bioscience distribution; bio-agriculture and ecosystem support. 

    Surprisingly, life sciences are South Carolina’s fastest-growing industry -- not more expected industries like automotive, tires, or aerospace, notes Erin Ford, Interim CEO of SCBIO -- a nonprofit dedicated to building, advancing and growing life sciences here. 

    “A 2017 study by USC's Moore School of Business showed 402 life science companies in South Carolina –  that’s grown to over 700 today.  It employed over 43,000 South Carolinians and generated $12 billion in impact,” said Ms. Ford. 

    To read the complete story, please click here...

  • sam patrick posted an article
    Premier Medical is conducting one of the largest-scale Next-gen Sequencing initiatives in USA see more

    US Senator Lindsey Graham recently viewed one of the largest variant surveillance initiatives in the nation currently underway at Premier Medical Laboratory Services (PMLS). At the PMLS facility headquartered in Greenville, SC, Next Generation Sequencing (NGS) enables the collection of data needed to study the efficacy of current COVID-19 vaccinations and the detection of new mutations of the SARS CoV-2 virus; like that of the Delta variant which has rapidly spread through India and the UK and now is present in the US. With the capability to monitor 84,000 COVID samples per week, the laboratory has the technology to allow the CDC and state health departments to detect this variant’s spread in the US along with any other novel variants of SARS CoV-2. 

    “This lab, right here in South Carolina, is testing variants for the entire country, and they are one of the first labs to invest heavily in variant testing to make sure that if there is a second comeback of the virus, we will get ahead of it.” Senator Graham stated alongside Kevin Murdock, CEO and Michael Conroy, VP of Compliance of PMLS. Senator Graham went on to speak about the new and emerging variants including the Delta strain, saying that, “Viruses try to survive. They will replicate. They will try to penetrate the vaccines. This is a war between science and the virus, and the virus is very clever.”

    According to Dr. Fauci, the Delta variant may be associated with a higher risk of hospitalization and is more contagious than the original COVID-19 strain – Approximately 40% more contagious, but scientists are still trying to pin down the exact number, with estimates ranging from 30% to 100%, as reported by UK Secretary of State for Health and Social Care, Matt Hancock. 

    Recent NIH studies have shown that while two doses of the Pfizer vaccine were 88% effective against the Delta variant, two doses of the AstraZeneca shot were  only 60% effective against the strain. With just under half of the American population having not been vaccinated, as of June 3, Next Generation Sequencing is vital in continued efforts to contain the virus and to keep hospitalization rates low.

    Senator Graham expressed that that PMLS has both provided tremendous capability to the public sector for the nation’s COVID response and that it allowed the population to get on with their lives, as the more testing that is conducted, the more is understood about the nature of the illness. Along these same lines, to help the US continue in its progress made against the COVID-19 virus, Premier Medical Laboratory Services plans to provide the data on the new variants that is now needed with their expansive Next Generation Sequencing initiative.

    Sources:

    https://www.whitehouse.gov/briefing-room/press-briefings/2021/06/03/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-40/

    https://www.cnbc.com/2021/06/08/fauci-says-us-must-vaccinate-more-people-before-delta-becomes-dominant-covid-variant-in-america.html

    ###

    About PMLS

    Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including Clinical Laboratory Improvement Amendments (CLIA) and COLA. PMLS prides itself on providing high complexity testing with unmatched turnaround times of results and one of the highest testing capacities in the nation. Their testing menu includes pharmacogenomics, COVID-19 testing, advanced cardiovascular testing, diabetes panels, women’s wellness panels, allergen specific Ige blood testing, toxicology, and a first of its kind predictive genetic test for type II diabetes, DiabetestPredict.

    PMLS also offers Virtual Lab, an infrastructure limitation solution allowing other laboratories to utilize PMLS’ fully-automated robotic workflow and team of 360 employees. With this, labs can largely increase their testing capacity and efficiency while bypassing the need to purchase new equipment or endure waiting time of weeks or more for shipping, installation, and validation. For more information, please visit www.PreMedInc.com or call  855-501-1023.

  • sam patrick posted an article
    Despite COVID, DPX continues to advance see more

    Columbia, SC – DPX Technologies, a manufacturer of laboratory consumables for sample preparation, continues with business expansion. This expansion includes the development of new product lines for proteomics and genomics testing and the construction of a large storage facility. 

    As an essential company, DPX continued operating during the pandemic and used this time to focus on product and Intellectual Property development. During 2020, DPX launched a new product and method for automated size exclusion chromatography. The size exclusion chromatography product line positions DPX in the market for proteomics testing, which diversifies their product offerings. DPX also initiated research and development on a new product line for nucleic acid purification and recently obtained a NSF Phase 1 SBIR award to further this research. 

    The business will continue with their expansion plans by building a large storage facility. The additional square footage is needed to support the increasing demand of inventory for raw materials and finished goods. 

    “COVID-19 has emphasized the need for fast, automated sample preparation  for nucleic acids, and we are committed to providing these solutions,” said William Brewer, CEO of DPX Technologies. “As we continue to expand our product offerings into more market segments for bioanalytical testing, we will be better positioned for long term advancement.” DPX recently hired another molecular biologist, and is purchasing new equipment and instrumentation for nucleic acid analysis. The company has plans to hire additional R&D scientists to support application development for their clients and manufacturing staff.   

    DPX has been manufacturing pipette tips for sample preparation since 2007 and specializes in developing custom products and workflows for a diverse client base.

     

    About DPX Technologies

    DPX is committed to providing innovative sample purification solutions. We collaborate with our customers to provide the high-quality products they need for complex chemical and biological analysis. 

     

  • sam patrick posted an article
    Vigilent Labs to call Charleston, South Carolina home see more

    Compliments of Charleston Post and Courier

    Congratulations to our colleagues in Charleston County for this excellent announcement, advancing the growth of life sciences in South Carolina.  Read the full story here.

     

    A technology firm with ties to the U.S. defense industry said Thursday it will invest nearly $105 million in a facility on the former Navy base in North Charleston that the company says will manufacture COVID-19 test kits.

    Vigilent Labs said it will hire 400 workers to produce FDA-approved test kits that can detect COVID-19 antibodies and antigens in 10 minutes or less.

    Manufacturing will begin in December and the company said it also will move its headquarters to the site at 1105 Truxton Ave. Vigilent is currently based in Alexandria, Va., near the nation’s capital, and it was incorporated in Wyoming.   Read on for full details.

  • sam patrick posted an article
    DPX publishes new application note see more

    DPX recently published a new application note “Automated Method for High-Throughput LC-MS/MS Quantitation of Testosterone from Serum: An Improved Validated Method” where a new ultra pure grade filtration tip was introduced. The method for the extraction of testosterone from serum used Low Porosity Filtration Tips- Ultra Pure (LPFT-UP) and incorporated a ZnSOsolution in addition to acetonitrile on a Hamilton Heater Shaker (HHS) for improved recovery and precision during protein precipitation. The LPFT-UP provide a high purity filtration media for methods with very low detection limits.

    Patient samples had a calculated recovery of testosterone at 99.5% with no detected matrix effects. This demonstrates that the use of ZnSO4 and acetonitrile is very efficient in extracting testosterone, and the use of ultra pure grade tips (LPFT-UP) resulted in negligible losses. The introduction of Low Porosity Filtration tips- Ultra Pure provides a new product for low detection level methods.

    “We are really excited to expand our product offering for steroid testing,” said Carmen Adamson, brand manager. DPX plans to expand on the research and development to include a full panel of steroids. “Testosterone imbalance can signal a problem in both men and women. This method provides an accurate and precise tool to aid in that determination,” said Evan DiVirgilio, application scientist. DPX continues to provide methods for efficient sample processing for clinical and forensic laboratories.

    DPX Technologies manufactures patented sample preparation products and specializes in custom workflows for a diverse client base including clinical, forensic, food safety, and pharmaceutical industries. Their products offer INTip™ sample preparation solutions that are compatible with semi-automated and fully automated liquid handling systems. This enables high sample throughput and high laboratory efficiency.

    # # #

    About DPX Technologies

    DPX is committed to providing innovative sample purification solutions. We collaborate with our customers to provide the high-quality products they need for complex chemical and biological analysis.